• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

雌激素和孕激素受体表达与子宫内膜癌无病生存期的相关性研究

Researches on the Correlation Between Estrogen and Progesterone Receptors Expression and Disease-Free Survival of Endometrial Cancer.

作者信息

Ren Siling, Wu Jingxian, Yin Wanchun, Liao Qianqian, Gong Sailan, Xuan Beibei, Mu Xiaoling

机构信息

Department of Gynecology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, People's Republic of China.

Department of Pathology, Chongqing Medical University, Chongqing 400016, People's Republic of China.

出版信息

Cancer Manag Res. 2020 Dec 9;12:12635-12647. doi: 10.2147/CMAR.S263219. eCollection 2020.

DOI:10.2147/CMAR.S263219
PMID:33335423
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7737816/
Abstract

OBJECTIVE

In this study, 345 patients with endometrial carcinoma (EC) were selected to investigate the correlation between ER/PR status and the EC disease-free survival (DFS) rate.

METHODS

The intensity and proportion of tumor cell expression of estrogen receptors and progesterone receptors (ER/PR) status of 345 postoperative tumor specimens in ECs were independently assessed semi-quantitatively by two pathologists using immunohistochemistry, the summed score ranged from 0 to 8 points was worked out by adding proportion score and intensity score based on the breast cancer hormone receptor immunohistochemical Allred scoring system. The association between DFS in ECs and ER/PR expression (intensity, proportion and summed score) was assessed using Cox regression analysis. Gene expression data were obtained from The Cancer Genome Atlas research network (TCGA).

RESULTS

According to inclusion criteria, 201 type I and 144 type II EC patients were enrolled in this study. In the univariate analysis of type I endometrial carcinoma, the intensity, proportion and summed score of ER/PR status were significantly correlated with DFS. After adjusting for factors known to significantly impact survival, the influence of ER/PR status on DFS is generally decreased but the correlation is still significant. In the univariate analysis of type II endometrial carcinoma, the intensity, proportion and summed score of ER/PR status were significantly correlated with DFS. After adjusting for factors known to significantly impact survival, the influence of ER status on DFS is generally decreased, but the correlation is still significant, the effect of PR expression on DFS is not statistically significant.

CONCLUSION

Higher ER/PR expression status was associated with better DFS in patients with type I endometrial cancer after adjusting for known factors that significantly affect survival. In patients with type II endometrial cancer, patients with positive ER expression were significantly associated with better DFS. However, the effect of PR expression on DFS was not statistically significant.

摘要

目的

本研究选取345例子宫内膜癌（EC）患者，探讨雌激素受体/孕激素受体（ER/PR）状态与EC无病生存率（DFS）之间的相关性。

方法

两名病理学家采用免疫组织化学方法对345例EC术后肿瘤标本中肿瘤细胞雌激素受体和孕激素受体（ER/PR）状态的表达强度和比例进行独立半定量评估，根据乳腺癌激素受体免疫组织化学奥尔雷德评分系统，将比例评分与强度评分相加得出总分，范围为0至8分。采用Cox回归分析评估EC患者DFS与ER/PR表达（强度、比例和总分）之间的关联。基因表达数据来自癌症基因组图谱研究网络（TCGA）。

结果

根据纳入标准，本研究纳入201例I型和144例II型EC患者。在I型子宫内膜癌的单因素分析中，ER/PR状态的强度、比例和总分与DFS显著相关。在对已知显著影响生存的因素进行调整后，ER/PR状态对DFS的影响总体上有所降低，但相关性仍然显著。在II型子宫内膜癌的单因素分析中，ER/PR状态的强度、比例和总分与DFS显著相关。在对已知显著影响生存的因素进行调整后，ER状态对DFS的影响总体上有所降低，但相关性仍然显著，PR表达对DFS的影响无统计学意义。

结论

在对已知显著影响生存的因素进行调整后，I型子宫内膜癌患者中较高的ER/PR表达状态与较好的DFS相关。在II型子宫内膜癌患者中，ER表达阳性的患者与较好的DFS显著相关。然而，PR表达对DFS的影响无统计学意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/febe/7737816/42cc55d87509/CMAR-12-12635-g0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/febe/7737816/aa26867e6f86/CMAR-12-12635-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/febe/7737816/839b51d334ad/CMAR-12-12635-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/febe/7737816/612b9f0082bb/CMAR-12-12635-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/febe/7737816/98cb76ed0c92/CMAR-12-12635-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/febe/7737816/2301974fc0c0/CMAR-12-12635-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/febe/7737816/0bdc2fbf129e/CMAR-12-12635-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/febe/7737816/22db16bf10dc/CMAR-12-12635-g0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/febe/7737816/42cc55d87509/CMAR-12-12635-g0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/febe/7737816/aa26867e6f86/CMAR-12-12635-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/febe/7737816/839b51d334ad/CMAR-12-12635-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/febe/7737816/612b9f0082bb/CMAR-12-12635-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/febe/7737816/98cb76ed0c92/CMAR-12-12635-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/febe/7737816/2301974fc0c0/CMAR-12-12635-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/febe/7737816/0bdc2fbf129e/CMAR-12-12635-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/febe/7737816/22db16bf10dc/CMAR-12-12635-g0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/febe/7737816/42cc55d87509/CMAR-12-12635-g0008.jpg

相似文献

1
Researches on the Correlation Between Estrogen and Progesterone Receptors Expression and Disease-Free Survival of Endometrial Cancer.雌激素和孕激素受体表达与子宫内膜癌无病生存期的相关性研究
Cancer Manag Res. 2020 Dec 9;12:12635-12647. doi: 10.2147/CMAR.S263219. eCollection 2020.
2
ER and PR expression and survival after endometrial cancer.子宫内膜癌的 ER 和 PR 表达与生存。
Gynecol Oncol. 2018 Feb;148(2):258-266. doi: 10.1016/j.ygyno.2017.11.027. Epub 2017 Dec 6.
3
[The value of progesterone and estrogen receptors expression in tissue microarray method in prognosis of patients with endometrioid endometrial cancer].组织芯片法检测孕激素和雌激素受体表达在子宫内膜样腺癌患者预后中的价值
Ginekol Pol. 2013 Feb;84(2):95-101. doi: 10.17772/gp/1547.
4
The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification.I 级和 II 级子宫内膜样腺癌中雌激素和孕激素受体的预后意义：激素受体在风险分层中的作用。
J Gynecol Oncol. 2019 Jan;30(1):e13. doi: 10.3802/jgo.2019.30.e13. Epub 2018 Oct 29.
5
Impact of oestrogen and progesterone receptor expression in the cancer cells and myometrium on survival of patients with endometrial cancer.癌细胞和子宫肌层中雌激素及孕激素受体表达对子宫内膜癌患者生存的影响。
J Obstet Gynaecol. 2018 Jan;38(1):96-102. doi: 10.1080/01443615.2017.1328591. Epub 2017 Aug 1.
6
Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer.一大群子宫内膜样子宫内膜癌患者中雌激素受体α和β以及孕激素受体A和B的表达
Gynecol Oncol. 2009 Mar;112(3):537-42. doi: 10.1016/j.ygyno.2008.10.032. Epub 2008 Dec 23.
7
The variation and clinical significance of hormone receptors and Her-2 status from primary to metastatic lesions in breast cancer patients.乳腺癌患者从原发性病灶到转移病灶的激素受体及人表皮生长因子受体2（Her-2）状态的变化及其临床意义
Tumour Biol. 2016 Jun;37(6):7675-84. doi: 10.1007/s13277-015-4649-7. Epub 2015 Dec 21.
8
[Correlation between estrogen receptor status and clinicopathologic parameters in endometrial cancer: a comparative study by immunohistochemistry using different scoring systems].子宫内膜癌中雌激素受体状态与临床病理参数的相关性：使用不同评分系统的免疫组织化学比较研究
Zhonghua Bing Li Xue Za Zhi. 2013 Aug;42(8):509-14.
9
The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration study.重新探讨子宫内膜癌中雌激素和孕激素受体表达的截断值：欧洲子宫内膜癌个体化治疗网络合作研究。
Hum Pathol. 2021 Mar;109:80-91. doi: 10.1016/j.humpath.2020.12.003. Epub 2020 Dec 15.
10
Fatty acid synthase is a potential therapeutic target in estrogen receptor-/progesterone receptor-positive endometrioid endometrial cancer.脂肪酸合酶是雌激素受体/孕激素受体阳性子宫内膜样子宫内膜癌的潜在治疗靶点。
Oncology. 2013;84(3):166-73. doi: 10.1159/000342967. Epub 2013 Jan 9.

引用本文的文献

1
Comprehensive Review of Endometrial Cancer: New Molecular and FIGO Classification and Recent Treatment Changes.子宫内膜癌综合综述：新的分子和国际妇产科联盟（FIGO）分类以及近期治疗变化
J Clin Med. 2025 Feb 19;14(4):1385. doi: 10.3390/jcm14041385.
2
Association of CYP7B1 expression with the prognosis of endometrial cancer: a retrospective study.CYP7B1 表达与子宫内膜癌预后的相关性：一项回顾性研究。
World J Surg Oncol. 2024 Sep 17;22(1):251. doi: 10.1186/s12957-024-03504-4.
3
Utility of ER, p53, CEA and Napsin A in Histological Subtyping of Endometrial Carcinoma and Their Correlation with Clinicopathological Prognostic Parameters: Experience from a Referral Institute.

本文引用的文献

1
Two Distinct Tumorigenic Processes in Endometrial Endometrioid Adenocarcinoma.子宫内膜样腺癌中两种不同的致瘤过程。
Am J Pathol. 2020 Jan;190(1):234-251. doi: 10.1016/j.ajpath.2019.09.022. Epub 2019 Nov 13.
2
Do estrogen, progesterone, P53 and Ki67 receptor ratios determined from curettage materials in endometrioid-type endometrial carcinoma predict lymph node metastasis?刮宫标本中雌孕激素受体、P53 及 Ki67 受体比值与子宫内膜样型子宫内膜癌淋巴结转移的关系
Curr Probl Cancer. 2020 Feb;44(1):100498. doi: 10.1016/j.currproblcancer.2019.07.003. Epub 2019 Jul 26.
3
Selecting Adjuvant Treatment for Endometrial Carcinoma Using Molecular Risk Factors.
雌激素受体、p53、癌胚抗原和 napsin A 在子宫内膜癌组织学亚型分类中的应用及其与临床病理预后参数的相关性：来自一家转诊机构的经验
Iran J Pathol. 2024 Spring;19(2):236-243. doi: 10.30699/IJP.2024.2008693.3154. Epub 2024 Jan 29.
4
Analysis of Prognostic Factors and Cancer-Specific Survival in Patients with Undifferentiated and Dedifferentiated Endometrial Carcinoma Undergoing Various Postoperative Adjuvant Therapies.接受各种术后辅助治疗的未分化和去分化子宫内膜癌患者的预后因素及癌症特异性生存分析
Cancer Manag Res. 2024 Jun 4;16:559-573. doi: 10.2147/CMAR.S466022. eCollection 2024.
5
Roles of estrogen receptor α in endometrial carcinoma (Review).雌激素受体α在子宫内膜癌中的作用（综述）
Oncol Lett. 2023 Oct 25;26(6):530. doi: 10.3892/ol.2023.14117. eCollection 2023 Dec.
6
Effect of adenomyosis on prognosis of patients with endometrial cancer.子宫腺肌病对子宫内膜癌患者预后的影响。
Rev Assoc Med Bras (1992). 2023 Jul 17;69(7):e20221720. doi: 10.1590/1806-9282.20221720. eCollection 2023.
使用分子危险因素选择子宫内膜癌的辅助治疗。
Curr Oncol Rep. 2019 Jul 31;21(9):83. doi: 10.1007/s11912-019-0825-z.
4
High-Grade Endometrial Carcinomas: Classification with Molecular Insights.高级别子宫内膜癌：基于分子见解的分类
Surg Pathol Clin. 2019 Jun;12(2):343-362. doi: 10.1016/j.path.2019.02.003.
5
Fertility-preserving treatment of stage IA, well-differentiated endometrial carcinoma in young women with hysteroscopic resection and high-dose progesterone therapy.年轻女性IA期高分化子宫内膜癌经宫腔镜切除及大剂量孕激素治疗的生育力保留治疗
Taiwan J Obstet Gynecol. 2019 Jan;58(1):90-93. doi: 10.1016/j.tjog.2018.11.017.
6
Endocrine therapy in endometrial cancer: An old dog with new tricks.子宫内膜癌的内分泌治疗：老药新用。
Gynecol Oncol. 2019 Apr;153(1):175-183. doi: 10.1016/j.ygyno.2018.12.018. Epub 2019 Jan 5.
7
DNMT3A/3B overexpression might be correlated with poor patient survival, hypermethylation and low expression of ESR1/PGR in endometrioid carcinoma: an analysis of The Cancer Genome Atlas.DNMT3A/3B 过表达可能与子宫内膜样癌患者生存不良、ESR1/PGR 高甲基化和低表达相关：对癌症基因组图谱的分析。
Chin Med J (Engl). 2019 Jan 20;132(2):161-170. doi: 10.1097/CM9.0000000000000054.
8
The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification.I 级和 II 级子宫内膜样腺癌中雌激素和孕激素受体的预后意义：激素受体在风险分层中的作用。
J Gynecol Oncol. 2019 Jan;30(1):e13. doi: 10.3802/jgo.2019.30.e13. Epub 2018 Oct 29.
9
Luteinizing Hormone/Human Chorionic Gonadotropin Receptor Immunohistochemical Score Associated with Poor Prognosis in Endometrial Cancer Patients.黄体生成素/人绒毛膜促性腺激素受体免疫组织化学评分与子宫内膜癌患者预后不良相关。
Biomed Res Int. 2018 Apr 2;2018:1618056. doi: 10.1155/2018/1618056. eCollection 2018.
10
Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study.雌激素受体、孕激素受体和 L1 细胞黏附分子表达对基于组织学的子宫内膜癌复发预测模型的增值作用：ENITEC 协作研究。
Int J Gynecol Cancer. 2018 Mar;28(3):514-523. doi: 10.1097/IGC.0000000000001187.